



Corporate Presentation

A Breakthrough Neuropsychiatry Company

January 2025

NYSE American: CYBN
Cboe CA: CYBN

Cautionary Statement

The information contained in this presentation has been prepared by Cybin Inc. and its affiliates (“Cybin” or the “Company”). The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly available information, internally developed data and third party information from other sources; (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company; (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company; and (d) is for information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Where any opinion or belief is expressed in this presentation, it is based on certain assumptions and limitations and is an expression of present opinion or belief only. The third-party information has not been independently verified. While the Company may not have verified the third-party information, it believes that it obtained the information from reliable sources and has no reason to believe it is not accurate in all material respects. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. Cybin disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual's circumstances are different. Readers should consult with their own professional advisors regarding their particular circumstances. In making an investment decision, investors should not rely solely on the information contained in this presentation. The delivery of this presentation, at any time, will not imply that the information contained in the presentation is correct as of any time subsequent to the date set forth on the cover page of the presentation or the date at which such information is expressed to be stated, as applicable. No securities commission, exchange or similar regulatory authority in Canada or the United States has reviewed or in any way opined on the merits of this presentation, and any representation to the contrary is an offence.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements in this presentation constitute forward-looking information or forward-looking statements, within the meaning of applicable securities legislation (together, “forward looking statements”). All statements, other than statements of historical fact contained in this presentation, including, without limitation, statements regarding Cybin's future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only Cybin's expectations, estimates and projections regarding future events. These statements are not guaranteeing future performance and they involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements.

Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Risk Factors that could cause actual results, performance or achievement to differ materially from those indicated in the forward-looking statements include, but are not limited to the following: regulatory, legislative, legal or other developments with respect to its operations or business; general economic conditions and financial markets; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of disease outbreaks; conflicts of interest; uninsurable risks; and litigation and other factors beyond the Company's control. Readers are cautioned that the foregoing list and the risk factors under the heading “Risk Factors” are not exhaustive. The forward-looking information and forward-looking statements included in this presentation are made as of the date of this presentation. The Company does not undertake any obligation to update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities law. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Third party information has not been independently verified. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information.

RISK FACTORS

There are a number of risk factors that could cause future results to differ materially from those described herein. A discussion of the principal risk factors relating to the Company's operations and business appear in the Company's most recently filed management's discussion and analysis and the annual information form, which are available under the Company's profile on www.sedarplus.ca and with the United States Securities and Exchange Commission on EDGAR at www.sec.gov. Additional risks and uncertainties, including those that the Company is not aware of currently, or that it currently deems immaterial, may also adversely affect the Company's business or any investment therein. All of the forward-looking statements made in this presentation are qualified by these cautionary statements and other cautionary statements or other factors contained herein. Although management believes that the expectations conveyed by forward-looking statements herein are reasonable based on information available on the date such forward-looking statements are made, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The forward-looking statements contained herein are presented for the purposes of assisting readers in understanding the Company's plan, objectives and goals and may not be appropriate for other purposes. The reader is cautioned not to place undue reliance on forward-looking statements.

CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION

To the extent that any forward-looking statement in this presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking statements generally, are, without limitation, based on the assumptions and subject to the risks set out above under the heading “Cautionary Statement Regarding Forward-Looking Information”. The Company's actual financial position and results of operations may differ materially from management's current expectations and, as a result, the Company's revenue and expenses.

CAUTIONARY NOTE REGARDING REGULATORY MATTERS

The Company conducts research and development and is focused on developing and commercializing psychedelic-inspired regulated medicines. The Canadian, United States and Ireland federal governments regulate drugs. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act (Canada), a Schedule I drug under the Controlled Substances Act (United States) and a Schedule I controlled substance in Ireland under the Misuse of Drugs Act, 1977, 1984 and 2015, the Misuse of Drugs Regulations 2017 and the Criminal Justice (Psychoactive Substances) Act 2010. Health Canada, the Food and Drug Administration in the United States and such similar regulatory authorities in Ireland have not approved psilocybin as a drug for any indication. The Company does not deal with psychedelic substances except indirectly within laboratory and clinical trial settings conducted within approved regulatory frameworks in order to identify and develop potential treatments for medical conditions and, further, does not have any direct or indirect involvement with illegal selling, production or distribution of any substances in jurisdictions in which it operates. No product will be commercialized prior to applicable legal or regulatory approval. For these reasons, the Company may be (a) subject to heightened scrutiny by regulators, stock exchanges, clearing agencies and other authorities, (b) susceptible to regulatory changes or other changes in law, and (c) subject to risks related to drug development, among other things. There are a number of risks associated with the business of the Company. The Company makes no medical, treatment or health benefit claims about the Company's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company's performance and operations.

DRUG DEVELOPMENT

Drug development involves long lead times, is very expensive and involves many variables of uncertainty. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company. Every patient treated during future studies can change those assumptions either positively (to indicate a faster timeline to new drug applications and other approvals) or negatively (to indicate a slower timeline to new drug applications and other approvals). This presentation contains certain forward-looking statements regarding anticipated or possible drug development timelines. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company's development efforts to date.

INDUSTRY INFORMATION

This presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although the Company believes these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. The Company has not independently verified any of the data from third party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed.

US DISCLAIMER

This corporate overview is not a prospectus or an offering memorandum pursuant to applicable United States securities laws. The securities of Cybin may not be offered or sold in the “United States”, or to, or for the account or benefit of, “U.S. persons” as such terms are defined in Regulation S under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), unless pursuant to the registration requirements of the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements. The securities of Cybin have not been approved or disapproved by the United States Securities and Exchange Commission, or any other securities commission or regulatory authority in the United States, nor have any of the foregoing authorities passed upon or endorsed the merits of any of the securities of Cybin nor have they approved this presentation or confirmed the accuracy or adequacy of the information contained in this presentation. Any representation to the contrary is a criminal offense.

Changing Minds: Redefining the Standard of Care in Mental Health

Cybin is developing **differentiated, next-generation therapeutics** with the potential to **improve clinical outcomes and address key unmet needs** for people with mental health conditions¹

A Novel Treatment Approach to Neuropsychiatry

Cybin is advancing **intermittent treatments** with potential **rapid-onset, long-lasting clinical efficacy** in treating depression and anxiety

Unlike current treatments that only address symptoms, our therapies **target underlying causes in neural circuitry** that lead to mental health disorders

We Are an Advanced Clinical-Stage Neuropsychiatry Company Approaching Key Near-Term Milestones¹

1

Two proprietary clinical programs, CYB003 and CYB004, targeting depression and anxiety disorders with **positive Phase 2 safety and efficacy results**

2

Lead program CYB003, which has been granted **U.S. Food and Drug Administration Breakthrough Therapy Designation** is in **Phase 3 development** for the **adjunctive treatment of Major Depressive Disorder (“MDD”)**

3

Robust pipeline of differentiated assets with potential for expansion into **additional neuropsychiatry indications with high unmet need affecting >200M people in the U.S.**²

4

Strong Intellectual Property Portfolio:
over 70 granted patents, over 220 patent applications pending

5

Well-Capitalized to move programs forward with cash position of **C\$154.3 million** as of September 30, 2024

Exceptional Team Pedigree With Successful Track Record of Bringing Drugs to Market¹



Doug Drysdale
Chief Executive
Officer



**Amir Inamdar MBBS,
DNB(Psych),FFPM**
Chief Medical Officer



**Alex
Nivorozhkin, Ph.D**
Chief Scientific
Officer



Aaron Bartlone
Chief Operating
Officer



Tom Macek
SVP, Clinical
Development



**Atul R.
Mahabeshwarkar,
M.D., DLFAPA**
SVP, Clinical
Development



**Allison
House-Gecewicz**
SVP, Clinical
Operations



**Geoff Varty
Ph.D.**
Head of
R&D

- Combined 60 Investigational New Drug (IND) applications, 37 exits
- Combined 300 peer-reviewed publications by scientific leadership

Trintellix

Celexa
citalopram HBr

Lexapro
escitalopram oxalate

Namenda
memantine HCl tablets

Sabril

Allegra

Anzemet
dolasetron mesylate injection/tablets

Latuda
(lurasidone HCl)

Rozerem
ramelteon 8-mg tablets

VANIQA

zolgensma

Saphris

Innovative Neuropsychiatry Pipeline of 5-hydroxytryptamine (“5-HT”) Receptor Agonists with Clinical Validation and Value-Driving Milestones

PROGRAM	INDICATION	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	NEXT MILESTONES ^{1,2,3}
CYB003 Deuterated Psilocin (Oral)	Adjunctive treatment of Major Depressive Disorder (MDD)	Phase 3 initiated Granted FDA Breakthrough Therapy Designation					1H25: initiate second pivotal study, EMBRACE
CYB004 Deuterated Dimethyltryptamine (Intramuscular)	Generalized Anxiety Disorder (GAD)	Phase 2 study dosing underway					1H25: Phase 2 GAD topline efficacy results
CYB005 Phenethylamines (Non-hallucinogenic doses)	CNS Disorders	Preclinical studies underway					

Pipeline Targets Neuropsychiatry Indications with High Unmet Need

	Addressable Market	Health Impact	Need for Improved Treatments
<u>CYB003</u> MDD	<p>>300 million people worldwide¹</p> <p>~21 million with MDD in the U.S.²</p>	<ul style="list-style-type: none"> • Suicide risk is 20x higher for an individual with vs. without depression³ • 50-75% of MDD patients have anxious depression⁴ 	<ul style="list-style-type: none"> • 2/3rds of patients do not experience relief with initial antidepressant treatment⁵ • SSRI/SNRI side effects: weight gain (20%)⁶, sexual dysfunction (up to 30%)⁷, GI disturbances* and insomnia (25%)⁸ • With 2nd and 3rd line treatments, efficacy decreases; intolerance and relapse rates increase⁹
<u>CYB004</u> GAD	<p>>300 million people with anxiety disorders worldwide¹⁰</p> <p>6.8 million with GAD in the U.S. (3.1% of population)¹¹</p>	<ul style="list-style-type: none"> • GAD is the most common anxiety disorder seen in primary care¹² • ~77% of adults with GAD have moderate to severe impairment¹³ 	<ul style="list-style-type: none"> • 50% of patients with GAD do not respond to first line treatment with SSRIs and SNRIs¹² • 57% of patients with anxiety do not adhere to SSRI/SNRIs, due to side effects¹⁴

Transforming the Treatment Paradigm for Mental Health^{5,6}

Barriers to accessing care with current treatments:

Low availability to see new patients

- **Only 18.5%** of U.S. psychiatrists available to see new patients¹

Long median wait times¹

- 67 days for in-person visits, 43 days for telepsychiatry

High frequency of visits for existing intermittent treatments

- Esketamine: 26 sessions²
- TMS: Total of up to 36 sessions (5 per week)³
- ECT: Total of 6-12 sessions (2-3 per week)⁴



CYB003 with **infrequent acute dosing** and **long-lasting relief** presents opportunity to:

- **Reduce** frequency of visits for existing patients
- **Lower barriers to timely care**

Notes:

- 1) Sun et al. (2023). Low availability, long wait times, and high geographic disparity of psychiatric outpatient care in the US. *General Hospital Psychiatry*, 84, 12–17. <https://doi.org/10.1016/j.genhosppsych.2023.05.012>
- 2) Esketamine package insert
- 3) Hutton et al. (2023). Dosing transcranial magnetic stimulation in major depressive disorder: Relations between number of treatment sessions and effectiveness in a large patient registry. *Brain stimulation*, 16(5), 1510–1521. <https://doi.org/10.1016/j.brs.2023.10.001>
- 4) Thirthalli, J., Naik, S. S., & Kunigiri, G. (2020). Frequency and Duration of Course of ECT Sessions: An Appraisal of Recent Evidence. *Indian journal of psychological medicine*, 42(3), 207–218. https://doi.org/10.4103/IJPSYM.IJPSYM_410_19
- 5) Forward-looking statements are subject to risks and assumptions. See "Cautionary Statement" on page 2 of this presentation.
- 6) Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Cybin is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain pilsocin and other analogues. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to Cybin. Such statements are informed by, among other things, regulatory guidelines for developing a drug with timeline safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and Cybin's development efforts to date.

Opportunity for Pipeline Expansion into Indications with Large Addressable Markets^{15,16}

	Indications with early studies supporting potential	U.S. Prevalence	Estimated Addressable Market*
Behavioral Disorders	Depression ¹	8.3% ⁸	28 million
	Anxiety Disorders / PTSD ²	19.1% / 3.6% ⁹	64 million / 12 million
	Bipolar Disorder ³	2.8% ¹⁰	9 million
	Substance Use / Addiction Disorders ⁴	14.5% ¹¹	48 million
	Eating Disorders ⁵	0.3–1.2% ¹²	1–4 million
Other CNS	Cluster Headaches / Migraine ⁶	0.1% / 12% ¹³	0.3 million / 40 million
	Chronic Pain Management ⁷	21% ¹⁴	70 million



Large opportunity for expansion into indications **affecting >200 million people in the U.S.**

CYB003


Deuterated Psilocin Program
Adjunctive Treatment of MDD

CYB003: An Acute Adjunctive Therapy with Potential for Durable Remission

An adjunctive therapy could potentially¹:

- ✓ Allow for immediate treatment without waiting to withdraw from background medications
- ✓ Prevent withdrawal symptoms, which could be severe for some patients after years of antidepressant use
- ✓ Eliminate logistical hurdles associated with titrating off existing medications
- ✓ Allow patients to retain some benefit from background medications even if the background medications are inadequate alone

Current MDD Treatment in the U.S.²



Majority of patients are being treated with background medication²

~70% of patients on SSRIs³/SNRIs³
~60% on antidepressant > 2 years
~44% on antidepressant > 5 years

CYB003 Program Overview

Novel treatment paradigm

- Intermittent dosing with rapid relief and long-lasting remission
- Adjunctive treatment for patients who do not experience relief with SSRIs

Best-in-class effect size

- Primary endpoint at 3 weeks: -13.75 point difference in change in Montgomery-Asberg Depression Rating Scale ("MADRS") from baseline between CYB003 (12mg and 16mg pooled) vs. placebo ($p < 0.0001$)

Robust, sustained efficacy at 12 months

- **100%** of participants were responsive to treatment and **71%** were in remission from depression 12 months after 2 doses (16 mg) in a Phase 2 study
- Mean ~23-point reduction in MADRS scores from baseline

Breakthrough Therapy Designation ("BTD")

- U.S. FDA BTD for adjunctive treatment of MDD
- Phase 2 data for CYB003 shows preliminary evidence of significant improvements over existing therapies

Upcoming Milestones^{1,2,3}

- Initiate second pivotal Phase 3 study (EMBRACE) in first half 2025

Notes:

- 1) Forward-looking statements are subject to risks and assumptions. See "Cautionary Statement" on page 2 of this presentation.
- 2) Subject to receipt of all necessary regulatory approvals from all applicable governmental authorities, including, as applicable, the academic and scientific organizations with which Cybin is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocin and other analogues. authorities, including, as applicable, the academic and scientific organizations with which Cybin is working. There are multiple risk factors regarding the ability to successfully commercially scale a chemically synthesized process to obtain psilocin and other analogues. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to Cybin. Such statements are informed by, among other things, regulatory guidelines for developing a drug with timeline safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and Cybin's development efforts to date.
- 3) Cybin is prioritizing the progression of its CYB003 program. The advancement of Cybin's CYB004, CYB005 and technology programs are all contingent on Cybin's ability to continue raising capital under its current and future financing arrangements. No assurances can be given that Cybin will be able to raise the additional capital that it may require for its anticipated future development.

Positive Phase 2 CYB003 Results in MDD

Rapid onset of effect

Improvement in symptoms after single dose

Large improvements in symptoms

At 3 weeks: 12 mg better than placebo on MADRS by 14.1 points ($p=0.0001$), Cohen's $d=2.31$
16 mg better than placebo on MADRS by 13 points ($p=0.008$), Cohen's $d=2.54$

Incremental benefit of 2nd dose

Average 5.8 points improvement on the MADRS after 2nd dose (12 mg)
>75% response rates and up to 79% remission rates (12 mg) after a 2nd dose


Durable efficacy at 12 months

Benefit sustained to 12 months with 71% remission rate and 100% response rate after 2 doses (16 mg)

Favorable safety and tolerability profile

All reported AEs¹ mild to moderate; no AEs of suicidality. No AEs reported at 12 months.

CYB003: Phase 2a Trial Design in MDD^{1,2,3}



Phase 1: Single ascending dose study (1-10 mg), n=12

Phase 2a: RCT in MDD patients (12 mg, n=24; 16 mg, n=12)

Key Inclusion Criteria:


- ✓ Moderate to severe MDD (MADRS ≥ 21)
- ✓ Inadequate response to antidepressant medication

Primary Endpoint:

- ✓ Reduction in depression symptoms (change in MADRS score) at Week 3 after a single dose* vs. placebo

Notes:
1) *Patients allowed to remain on stable doses of antidepressant medications
2) Primary efficacy assessed at Week 3; Optional 12 week follow up to assess durability of effects
3) Forward looking statements are subject to risks and assumptions. See "Cautionary Statement" on page 2 of this presentation. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to Cybin. Such statements are informed by, among other things, regulatory guidelines for developing a drug with timeline safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assumes the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and Cybin's development efforts to date.



Large Improvement in Depression Symptoms After a Single Dose of CYB003





Dose	Primary Endpoint*	Effect size	p-value
12 mg	-14.1	2.31	0.0001
16 mg	-12.99	2.54	0.0080

*Primary endpoint: difference in change from baseline in MADRS total score between CYB003 and placebo at 3 weeks


Robust, Sustained Improvements in Depression Symptoms at 12 Months



Response and Remission at 12 Months: 12 mg & 16 mg



Response and Remission at 12 Months: 16 mg – 2 Doses



Favorable Safety Profile of CYB003

- No AEs were reported at the 12-month follow up
- No reports of suicidal ideation or behavior or any long-term adverse sequelae

In the short-term study:

- No SAEs and no participant discontinued the study due to an AE
- Most common AEs were nausea, elevated blood pressure and headache
- Increases in blood pressure were transient and resolved without intervention
- No clinically relevant changes in chemistry, hematology markers or ECG parameters

12-Month Data Highlights: Phase 2 CYB003 Results in MDD

Robust, sustained improvements in depression symptoms



- Mean ~23-point reduction in MADRS scores from baseline at 12 months following 2 doses (16mg)
- Average baseline MADRS score was ~32

Durable response and remission rates



12 months after 2 doses (16 mg):

- 100% of patients were responders
- 71% of patients were in remission

Favorable safety and tolerability profile



- All reported AEs mild to moderate; no AEs of suicidality
- No AEs/SAEs reported in the 12 month follow up

Phase 3 PARADIGM Program Overview

Study design aligned with FDA guidance and two meetings with FDA


Addressing functional unblinding

Phase 3 underway

The pivotal program will consist of 2 studies plus an extension^{1,2,3}:

- APPROACH: Two-arm study of two doses of CYB003 vs. placebo
- EMBRACE: Three-arm study with a high dose, mid-dose, and placebo arm
- EXTEND: Long-term extension study that allows for open-label dosing or re-dosing for participants who did not respond in the first two studies or relapsed during the extension study
- Use of remote, independent, blinded raters
- Firewall effects reporting during the dosing session
- Long-term efficacy data points up to one year to outlast expectancy bias
- Multinational Phase 3 program will include more than 40 sites across 12 countries in the U.S. and Europe^{1,2,3}
- Study sites selected with clinical expertise and training in depression studies
- Clinical supplies manufactured and ready

PARADIGM: CYB003 Phase 3 Pivotal Program in MDD***



*Primary endpoint: MADRS change from baseline at 6 weeks


**Key secondary endpoint: MADRS change from baseline at 12 weeks

***Note: Forward-looking statements are subject to risks and assumptions. There is no assurance that timelines will be met. Anticipated timelines regarding drug development are based on reasonable assumptions informed by current knowledge and information available to the Company. Such statements are informed by, among other things, regulatory guidelines for developing a drug with safety studies, proof of concept studies, and pivotal studies for new drug application submission and approval, and assume the success of implementation and results of such studies on timelines indicated as possible by such guidelines, other industry examples, and the Company's development efforts to date.




Increased Awareness Among Healthcare Providers

In a survey of 430+ mental healthcare providers around the world:

Healthcare Provider Survey Results



Early Commercial Stakeholder Engagement Underway

Healthcare Providers & Patients 	Clinics 	Payers 
<ul style="list-style-type: none">• Prepare and educate• Understand and overcome potential barriers	<ul style="list-style-type: none">• Dosing room setup• Site and monitor education and training• REMS (Risk Evaluation and Mitigation Strategy) preparedness• Explore additional channels beyond existing centers	<ul style="list-style-type: none">• Data collection• Pharmacoeconomics• Reimbursement route optimization



CYB004

Deuterated Dimethyltryptamine (dDMT) Program
Generalized Anxiety Disorder

CYB004 Program Overview

Short-duration treatment with convenient dosing

- Short-duration treatment
- Intramuscular dosing is more convenient and patient-friendly vs. IV

Demonstrated proof-of-concept in depression and anxiety

- Strong datasets across 5 studies supporting characterization and dosing optimization for dDMT
- Robust efficacy in depression with improvements in anxiety scores
- Favorable safety profile

Robust IP Protection for DMT/dDMT

- >50 patents in support of CYB004 program including composition of matter protection

Target Product Profile for dDMT

Optimized with Data from 5 Clinical Studies

Completed Studies

- 1 Phase 1/2a DMT study in moderate to severe MDD (no SSRIs)
- 2 Phase 1 IV/IM DMT study
- 3 Phase 1 SSRI DDI study
- 4 Phase 1 Study of IV CYB004 (dDMT) and IV DMT
- 5 Phase 1 IM/IV dDMT study



Key Findings

Rapid and durable antidepressant and anxiolytic effect observed in DMT

- ✓ 47% of MDD patients in remission at 3 months
- ✓ Among the patients that achieved remission at 3 months, 64% had sustained remission at 6 months
- ✓ 40% of MDD patients in remission at 6 months
- ✓ Rapid improvement in anxiety and wellbeing scores
- ✓ IV DMT safe and well-tolerated

Characterized safe and well-tolerated IM route and dose selection for DMT and dDMT


DMT safe and well-tolerated when co-administered with SSRIs

Potential enhanced effect when given as adjunctive to SSRIs:


- ✓ 92% remission rate in SSRI cohort vs. 20% remission (non-SSRI cohort)

DMT Demonstrates Proof-of-Concept in Reducing Anxiety Symptoms^{1,2}

- ✓ Efficacy assessed as change from baseline in STAI-T scores
- ✓ Data from the MDD monotherapy (21.5 mg) and SSRI add on studies (27.5 mg)
- ✓ Observed to provide proximal de-risking of development in anxiety



CYB004 in GAD: Phase 2 Proof-of-Concept Study¹




- Moderate to severe GAD
- Concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed

- Primary endpoint: HAM-A
- Other endpoints: HAM-D, safety, EQ-5D-5L

Phase 2 study dosing underway

Value-Driving Milestones Across Development Pipeline^{1,2}



Thank You

NYSE American: CYBN
Cboe CA: CYBN

Contact: ir@cybin.com

References

SLIDE 6

1. World Health Organization. (2017). Depression and other common mental disorders: global health estimates. World Health Organization. <https://iris.who.int/handle/10665/254610>.
2. <https://www.nimh.nih.gov/health/statistics/major-depression>
3. American Association of Suicidology, 2014
4. Hopwood M. (2023). Anxiety Symptoms in Patients with Major Depressive Disorder: Commentary on Prevalence and Clinical Implications. *Neurology and therapy*, 12(Suppl 1), 5–12. <https://doi.org/10.1007/s40120-023-00469-6>
5. Little A. Treatment-resistant depression. *Am Fam Physician*. 2009;80:167–72.
6. Sussman et al. *J Clin Psychiatry*. 2001(Apr);62(4):256–260
7. Clayton AH, et al. *J Clin Psychiatry*. 2002 Apr;63(4):357–66.
8. Fava M, et al. *J Clin Psychopharmacol*. 2002;22(2):137–147.
9. Rush AJ et al. "Acute and longer-term outcomes in depressed outpatient requiring one or several treatment steps: A STAR*D report". *The American Journal of Psychiatry*. 2006. 163(11):1905–1917. Diagram represents anticipated treatment outcomes as patients cycle through the current depression treatment guidelines
10. Yang et al. (2021). Global, regional and national burden of anxiety disorders from 1990 to 2019: results from the Global Burden of Disease Study 2019. *Epidemiology and Psychiatric Sciences* 30, e36, 1–11. <https://doi.org/10.1017/S2045796021000275/>
11. <https://adaa.org/understanding-anxiety/generalized-anxiety-disorder-gad>
12. Ansara E. D. (2020). Management of treatment-resistant generalized anxiety disorder. *The mental health clinician*, 10(6), 326–334. <https://doi.org/10.9740/mhc.2020.11.326>
13. Kessler et al. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*, 62(6):617–27.
14. Stein et al. (2006). Antidepressant Adherence and Medical Resource Use Among Managed Care Patients With Anxiety Disorders. *Psychiatric Services*, 57(5): 673–680.

*Up to 37% suffer from nausea, diarrhea, constipation, vomiting, dry mouth, and rarely gastrointestinal bleeding (based on a review of package inserts)

SLIDE 7

1. Raison et al (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. *JAMA*, 330(9):843–853. doi:10.1001/jama.2023.14530; Davis et al (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*, 78(5):481–489. doi:10.1001/jamapsychiatry.2020.3285
2. Holze et al (2023). Lysergic Acid Diethylamide-Assisted Therapy in Patients With Anxiety With and Without a Life-Threatening Illness: A Randomized, Double-Blind, Placebo-Controlled Phase II Study. *Biological psychiatry*, 93(3), 215–223. <https://doi.org/10.1016/j.biopsych.2022.08.025>; Mitchell et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. *Nat Med* 29, 2473–2480. <https://doi.org/10.1038/s41591-023-02565-4>
3. Aaronson et al. (2024). Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial. *JAMA Psychiatry*, 81(6):555–562. doi:10.1001/jamapsychiatry.2023.4685
4. Bogenschutz et al. (2022). Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*, 79(10):953–962. doi:10.1001/jamapsychiatry.2022.2096; Noller, G. E., Frampton, C. M., & Yazar-Klosinski, B. (2018). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. *The American journal of drug and alcohol abuse*, 44(1), 37–46. <https://doi.org/10.1080/00952990.2017.1310218>
5. Peck et al. (2023). Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. *Nat Med* 29, 1947–1953. <https://doi.org/10.1038/s41591-023-02455-9>
6. Karst et al. (2010). The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series. *Cephalalgia*, 30(9), 1140–1144.; Schindler et al. (2024). Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. *Journal of the neurological sciences*, 460, 122993. <https://doi.org/10.1016/j.jns.2024.122993>; Schindler et al. (2021). Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*, 18(1), 534–543. <https://doi.org/10.1007/s13311-020-00962-y>
7. Robinson et al. (2024). Scoping Review: The Role of Psychedelics in the Management of Chronic Pain. *Journal of pain research*, 17, 965–973. <https://doi.org/10.2147/JPR.S439348>; Bornemann et al. (2024). Study protocol for "Psilocybin in patients with fibromyalgia: brain biomarkers of action". *Frontiers in psychiatry*, 15, 1320780. <https://doi.org/10.3389/fpsy.2024.1320780>
8. <https://www.nimh.nih.gov/health/statistics/major-depression>
9. <https://www.nimh.nih.gov/health/statistics/any-anxiety-disorder>; <https://www.nimh.nih.gov/health/statistics/post-traumatic-stress-disorder-ptsd>
10. <https://www.nimh.nih.gov/health/statistics/bipolar-disorder>
11. <https://wwwnc.cdc.gov/travel/yellowbook/2024/additional-considerations/substance-use>
12. <https://www.nimh.nih.gov/health/statistics/eating-disorders>
13. Wei et al (2018). Cluster Headache: Epidemiology, Pathophysiology, Clinical Features, and Diagnosis. *Annals of Indian Academy of Neurology*, 21(Suppl 1), S3–S8. https://doi.org/10.4103/aian.AIAN_349_17
14. <https://americanmigrainefoundation.org/resource-library/ampp/>; Rikard et al. (2023). Chronic Pain Among Adults — United States, 2019–2021. *MMWR Morb Mortal Wkly Rep*, 72:379–385.